B7-33 vs Telmisartan
Emerging vs FDA Approved
synergistic Potential synergistic effects for cardiac protection; both target complementary pathways involved in cardiac remodeling and fibrosis.
Molecular Data
B7-33 Telmisartan
Weight ~4,000 Da 514.62 Da
Half-life Not well characterized ~24 hours
Type Single-chain peptide Benzimidazole derivative (C33H30N4O2)
Key Benefits
B7-33
01 Potent anti-fibrotic activity across multiple organ systems
02 Improved vasodilation and vascular compliance
03 Cardioprotective effects and potential to attenuate cardiac remodeling
04 Much simpler to synthesize than native two-chain relaxin-2
05 Selective RXFP1 agonism with biased signaling profile
06 Preclinical efficacy in models of heart failure and fibrosis
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Dosing Protocols
B7-33
100-250mcg / Once daily
Anti-fibrotic / Cardiovascular support 100-250 mcg 1x daily
Telmisartan
20-80 mg/day / Once daily
Side Effects
B7-33
Injection site reactions (redness, mild irritation)
Potential transient hypotension due to vasodilatory effects
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Pre-existing hypotension or conditions exacerbated by vasodilation
Pregnancy or breastfeeding (no safety data available)
Concurrent use of potent antihypertensive agents without medical supervision
No human safety data exists -- all protocols are extrapolated from preclinical research
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
B7-33 Telmisartan
Status Emerging FDA Approved
References 5 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.